Seminars in Nephrology
Volume 24, Issue 3 , Pages 244-255 , May 2004

Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy

  • Osamu Hotta

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Osamu Hotta, MD, Director, Department of Nephrology, Sendai Shakaihoken Hospital, Tsutsumimachi 3-16-1, Aoba-ku, Sendai 981-8501, Japan
    • Department of Nephrology, Sendai Shakaihoken Hospital, Sendai, Japan

References 

  1. D’Amico G, Imbasciati E, Barbiano D, et al.  Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine. 1985;64:49–60
  2. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis. 1988;12:340–347
  3. Berger J, Hinglais N. Les depots intercapillaries d’IgA-IgG. J Urol Nephrol. 1968;74:694–695
  4. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Disease. Am J Kidney Dis. 1997;29:526–532
  5. Galla JH. IgA nephropathy. Kidney Int. 1995;47:377–387
  6. Kobayashi Y, Sano T, Hashizume K, et al.  Long-term prognosis of 366 IgA nephropathy patients. Nephrology. 2002;7(suppl):A97
  7. Julian BA. Treatment of IgA nephropathy. Semin Nephrol. 2000;20:277–285
  8. Glassock RJ. The treatment of IgA nephropathy (Status at the end of the millennium). J Nephrol. 1999;12:288–296
  9. Locatelli F, Pozzi C, Del Vecchio L, et al.  New therapeutic approaches in primary IgA nephropathy. Adv Nephrol. 1999;29:73–91
  10. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347:738–748
  11. Szeto CC, Lai FMM, To KF, et al.  The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–437
  12. Hotta O, Miyazaki M, Furuta T, et al.  Tonsillectomy and steroid pulse therapy significantly impact in patients with IgA nephropathy. Am. J. Kidney Dis. 2001;38:736–742
  13. Hotta O, Furuta T, Chiba S, et al.  Regression of IgA nephropathy (A repeat biopsy study). Am J Kidney Dis. 2002;39:493–502
  14. Hotta O, Taguma Y, Kurosawa K, et al.  Predictive value of small crescents in IgA nephropathy (Analysis of four patients showing a deteriorated renal function during a long follow-up period). Clin Nephrol. 1993;40:125–130
  15. Ferrario F, Napodano P, Rastaldi MP, et al.  Capillaritis in IgA nephropathy. Contrib Nephrol. 1995;111:8–12
  16. Neuringer JR, Brenner BM. Hemodynamic theory of progressive renal disease (A 10-year update in brief review). Am J Kidney Dis. 1993;22:98–104
  17. Eddy A. Molecular insights into renal fibrosis. J Am Soc Nephrol. 1996;7:2495–2508
  18. Johnson RJ, Herrera-Acosta J, Schreiner GF, et al.  Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med. 2002;346:913–923
  19. Maschio G, Alberti D, Janin G, et al.  Effect of angiotensin converting enzyme inhibitor benazapril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–945
  20. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term anti-hypertensive treatment induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. 1997;51:793–797
  21. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrogia) . Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1587–1863
  22. Ruggenenti P, Perna A, Gherardi G, et al.  Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359–364
  23. Brenner BM, Cooper ME, Zeeuw D, et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  24. Donadio JV, Bergstrath EJ, Offord KP, et al.  A controlled trial of fish oil in IgA nephropathy. N Engl J Med. 1994;331:1194–1199
  25. Pedrini MT, Levey AS, Lau J, et al.  The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal disease (a meta-analysis). Ann Intern Med. 1996;124:627–632
  26. Berger J, Yaneva H, Nabarra B, et al.  Recurrence of mesangial IgA deposition of IgA after renal transplantation. Kidney Int. 1975;7:232–241
  27. Odum J, Peh CA, Clarkson AR, et al.  Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant. 1994;9:309–312
  28. Wang AYM, MacMoune Lai F, Wai-Yin Yu A, et al.  Recurrent IgA nephropathy in renal transplant allograft. Am J Kidney Dis. 2001;38:588–596
  29. Sanfilippo F, Croker BP, Bollinger RR. Fate of four cadaveric renal allografts with mesangial IgA deposits. Transplantation. 1982;33:370–376
  30. Silva FG, Chander P, Pirani CL, et al.  Disappearance of mesangial IgA deposits after allograft transplantation. Transplantation. 1982;33:214–216
  31. Suzuki S, Nakatomi Y, Sato H, et al.  Haemophilus parainfluenzae antigen and antibody in renal biopsy samples and serum of patients with IgA nephropathy. Lancet. 1994;343:12–15
  32. Drew PA, Nieuwhof WN, Clarkson AR, et al.  Increased concentration of serum IgA antibodies to pneumococcal polysaccharides in patients with IgA nephropathy. Clin Exp Immunol. 1987;60:124–129
  33. Cohen AJ, Rosenstein ED. IgA nephropathy associated with disseminated tuberculosis. Arch Intern Med. 1985;145:554–556
  34. Tomino Y, Yagame M, Omata F, et al.  A case of IgA nephropathy associated with adeno herpes simplex viruses. Nephron. 1987;47:258–261
  35. Gregory MC, Hammond ME, Brewer ED. Renal deposition of cytomegalovirus antigen in immunoglobulin-A nephropathy. Lancet. 1988;2:11–14
  36. Nagy J, Uj M, Szucs G, et al.  Herpes virus antigens and antibodies in kidney biopsies and sera of IgA glomerulonephritic patients. Clin Nephrol. 1984;21:259–262
  37. Sato M, Kojima H, Takayama K, et al.  Glomerular deposition of food antigens in IgA nephropathy. Clin Exp Immunol. 1988;73:295–299
  38. Coppo R, Basoco B, Rollino C, et al.  Mediterranean diet and primary IgA nephropathy. Clin Nephrol. 1986;26:72–82
  39. Czerkinsky C, Koopman WJ, Jackson S, et al.  Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest. 1986;77:1931–1938
  40. Sinico RA, Fornasieri A, Oreni N, et al.  Polymeric IgA rheumatoid factor in idiopathic IgA mesangial nephropathy (Berger’s disease). J Immunol. 1986;137:536–541
  41. Ballardie FW, Brenchley PE, Williams S, et al.  Autoimmunity in IgA nephropathy. Lancet. 1988;2:588–592
  42. Wang MX, Walker RG, Kinkaid-Smith P. Clinicopathologic association of anti-endothelial cell antibodies in immunoglobulin A nephropathy and lupus nephritis. Am J Kidney Dis. 1993;22:378–386
  43. Fu YX, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol. 1999;17:399–433
  44. Sato Y, Hotta O, Taguma Y, et al.  IgA nephropathy with poorly developed lymphoepithelial symbiosis of the palatine tonsils. Nephron. 1996;74:301–308
  45. De Fijter JW, Eijgenraam JW, Braam CA, et al.  Deficient IgA1 immune response to nasal cholera toxin subunit B in IgA nephropathy. Kidny Int. 1996;50:952–961
  46. Roodnat JI, de Fijter JW, van Kooten C, et al.  Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Nephrol Dial Transplant. 1999;14:353–359
  47. Feehally J, Allen AC. Pathogenesis of IgA nephropathy. Ann Med Interne (Paris). 1999;150:91–98
  48. Hiki Y, Odani H, Takahashi M, et al.  Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 2001;59:1077–1085
  49. Odani H, Hiki Y, Takahashi M, et al.  Direct evidence for decreased sialylation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy by mass spectrometry. Biochem Biophys Rec Commun. 2000;271:268–274
  50. Tomana M, Novak J, Julian BA, et al.  Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999;104:73–81
  51. Ortmanns A, Ittel TH, Schnitzler N, et al.  Remission of IgA nephropathy following treatment of cytomegalovirus infection with ganciclovir. Clin Nephrol. 1998;49:379–384
  52. Kincaid-Smith P. Treatment of mesangial immunoglobulin A glomerulonephritis. Semin Nephrol. 1999;19:166–172
  53. Hung KY, Chen MY, Yen TS, et al.  Adult primary IgA nephropathy and common viral infections. J Infect. 1996;32:227–230
  54. Xie Y, Nishi S, Ueno M, et al.  The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861–1867
  55. Masuda Y, Terazawa K, Kawakami S, et al.  Clinical and immunological study of IgA nephropathy before and after tonsillectomy. Acta Otolaryngol. 1988;454(suppl):248–255
  56. Bene MC, Hurault de Ligny B, Kessler M, et al.  Tonsils in IgA nephropathy. Contrib Nephrol. 1993;104:153–161
  57. Horie A, Nakamura I, Odani H, et al.  MALDI-TOFMS analysis of structural alteration of O-glycosylated hinge peptides in serum IgA1 before and after tonsillectomy in IgA nephropathy. [Abstract] J Am Soc Nephrol. 2002;13:662A
  58. Lakkis FG, Arakelov A, Konieczny BT, et al.  Immunologic “ignorance” of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med. 2000;6:686–688
  59. Chalasani G, Dai Z, Konieczny BT, et al.  Recall and propagation of allospecific memory T cells independent of secondary lymphoid organs. Proc Natl Acad Sci U S A. 2002;99:6175–6180
  60. Andersson RA, Olaison G, Tysk C, et al.  Appendectomy and protection against ulcerative colitis. N Engl J Med. 2001;344:808–814
  61. Hotta O, Taguma Y, Sudo K, et al.  Limitation of kidney biopsy in detecting crescentic lesions in IgA nephropathy. Nephron. 1993;65:472–473
  62. Tolkoff-Rubin NE, Cosimi AB, Fuller T, et al.  IgA nephropathy in HLA-identical siblings. Transplantation. 1978;26:430–433
  63. Sinniah R. Occurrence of mesangial IgA and IgM deposits in a control necropsy population. J Clin Pathol. 1983;36:276–279
  64. Terasaki T, Sano M, Narita M, et al.  Ultrastructural study of gaps of the glomerular basement membrane in IgA nephropathy. Am J Nephrol. 1986;6:443–449
  65. Shigematsu H, Kobayashi Y, Tateno Y, et al.  Ultrastructural glomerular loop abnormalities in IgA nephritis. Nephron. 1982;30:1–7
  66. Kincaid-Smith P, Nicholls K. Mesangial IgA nephropathy. Am J Kidney Dis. 1983;3:90–102
  67. Benett WM, Kincaid-Smith P. Macroscopic hematuria in mesangial, IgA nephropathy (Correlation with glomerular crescent and renal dysfunction). Kidney Int. 1983;23:393–400
  68. Abe T, Kida H, Yoshimura M, et al.  Participation of extracapillary lesions in progression of IgA nephropathy. Clin Nephrol. 1986;25:37–41
  69. Hotta O, Yusa N, Ooyama M, et al.  Detection of urinary macrophages expressing the CD16 (FcγRIII) molecule (A novel marker of acute inflammatory glomerular injury). Kidney Int. 1999;55:1927–1934
  70. Hotta O, Yusa N, Kitamura H, et al.  Urinary macrophages as activity markers of renal injury. Clin Chim Acta. 2000;297:123–133
  71. Lagrue G, Sadreux T, Laurant J, et al.  Is there a treatment of mesangial IgA nephropathy. Clin Nephrol. 1981;14:161
  72. Sugiyama N. Clinicopathological study of the effectiveness of tonsillectomy in IgA nephropathy accompanied by chronic tonsillitis. Acta Otolaryngol. 1993;508(suppl):43–48
  73. Iino Y, Ambe K, Kato Y, et al.  Chronic tonsillitis and IgA nephropathy. Acta Otolaryngol. 1993;508(suppl):29–35
  74. Tamura S, Masuda Y, Inokuchi I, et al.  Effect and indication of for tonsillectomy in IgA nephropathy. Acta Otolaryngol. 1993;508:23–28
  75. Akagi H, Nishizaki K, Hattori K, et al.  Prognosis of tonsillectomy in patients with IgA nephropathy. Acta Otolaryngol. 1999;540(suppl):64–66
  76. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol. 1999;51:147–152
  77. Kataura A, Tsubota H. Clinical analysis of focus tonsil and related disease in Japan. Acta Otolaryngol. 1996;523(suppl):161–164
  78. Ono T, Jono M, Kito M, et al.  Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris. Acta Otolaryngol. 1983;401(suppl):12–16
  79. Matsutani S, Hotta O. Urinalysis after tonsillectomy in IgA nephropathy. [Abstract, in Japanese] Jpn J Nephrol. 2001;43:205
  80. Kobayashi Y, Fujii K, Hiki Y, et al.  Steroid therapy in IgA nephropathy (A retrospective study in heavy proteinuric cases). Nephron. 1988;48:12–17
  81. Kobayashi Y, Hiki Y, Kokubo T, et al.  Steroid therapy during the early stage of progressive IgA nephropathy (A 10-year follow-up study). Nephron. 1996;72:237–242
  82. Shoji T, Nakanishi I, Suzuki A, et al.  Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis. 2000;35:194–201
  83. Lai KN, Lai FM, Ho CP. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome (A long-term controlled trial). Clin Nephrol. 1986;26:174–180
  84. Welch TR, Fryer C, Shely E, et al.  Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr. 1992;121:474–477
  85. Waldo B, Wyatt RJ, Kelly DR, et al.  Treatment of IgA nephropathy in children (Efficacy of alternate-day prednisolone). Pedatr Nephrol. 1993;7:529–532
  86. Katafuchi R, Ikeda K, Mizumasa T, et al.  Controlled, prospective trial of steroid treatment in IgA nephropathy (A limitation of low-dose prednisolone therapy). Am J Kidney Dis. 2003;41:972–983
  87. Baldwin AS. The NF-kappa B and I kappa B proteins (New discoveries and insights). Annu Rev Immunol. 1996;14:649–683
  88. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions (Steroid treatment of rheumatic diseases revisited). Arthritis Rheum. 1998;41:761–767
  89. Migita K, Eguchi K, Kawabe Y, et al.  Apoptosis of induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Transplantation. 1997;63:583–587
  90. Bronnegard M. Steroid receptor number (Individual variation and downregulation by treatment). Am J Respir Crit Care Med. 1996;154:S28–33
  91. Sabir S, Werth VP. Pulse glucocorticoid. Inpatient Dermatol. 2000;18:437–445
  92. Pozzi C, Bolasco PG, Gogazzi G, et al.  Corticosteroids in IgA nephropathy (A randomized controlled trial). Lancet. 1999;353:883–887
  93. Locatelli F, Pozzi C, Vecchio LD, et al.  Combined treatment with steroids and azathioprine in IgA nephropathy (design of a prospective randomized multicentre trial). J Nephrol. 1999;12:308–311
  94. Tamura S, Ueki K, Ideura H, et al.  Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clin Nephrol. 2001;55:192–195
  95. Yoshikawa N, Hiroshi I, Sakai T, et al.  A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol. 1999;10:101–109
  96. Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002;13:142–148
  97. Oshima S, Kubota T, Kawamura O, et al.  Long-term follow-up of prednisolone and cyclophosphamide therapy in IgA nephropathy. Nephrology. 1999;5(suppl):A20–A21
  98. Allison AC, Kowalski WJ, Muller CJ, et al.  Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc. 1993;25:67–70
  99. Novack R, Brick R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet. 1997;349:774
  100. Chen XM, Zhang YP, Qui Q, et al.  Short-term effects of mycophenolate mofetil on IgA nephropathy. [Abstract] J Am Soc Nephrol. 1999;10:69A
  101. Chen X, Chen Pu, Cai G, et al.  A randomized control study of mycophenolate mofetil treatment in severe IgA nephropathy. [Abstract] J Am Soc Nephrol. 2002;13:14A
  102. Nagaoka R, Kaneko K, Ohtani Y. Mizoribine treatment for childhood IgA nephropathy. Pediatr Int. 2002;44:217–223
  103. Lai KN, Lai FM, Li PK, et al.  Cyclosporin treatment of IgA nephropathy (A short term controlled trial). BMJ. 1987;295:1165–1168
  104. Sato M, Hotta O, Tomioka S, et al.  Cohort study of advanced IgA nephropathy (Efficacy and limitations of corticosteroids with tonsillectomy). Nephron. 2003;93:137–145
  105. Pozzi C, Vecchio LD, Locatelli F. Can immunosuppressive therapy be useful in IgA nephropathy when the “point of no return” has already been exceeded?. Nephron. 2002;92:699–701
  106. Chauveau D, Droz D. Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib Nephrol. 1993;104:1–5

PII: S0270-9295(04)00007-5

doi: 10.1016/j.semnephrol.2004.01.005

Seminars in Nephrology
Volume 24, Issue 3 , Pages 244-255 , May 2004

Article Tools

* Image Usage & Resolution